Depo-Provera Lawsuit April 2026 Update: 3,490 Cases Filed, FDA Brain Tumor Warning Issued, and First Trial Set for December

The FDA Meningioma Warning — A Game-Changer for Plaintiffs

On December 17, 2025, the U.S. Food and Drug Administration formally approved a meningioma brain tumor warning for Depo-Provera CI (medroxyprogesterone acetate injectable, 150 mg/mL) and Depo-SubQ Provera 104 — the first federal regulatory acknowledgment that a confirmed link exists between the birth control injection and intracranial tumors.^[2]

The newly approved label language reads in full:

This regulatory development carries profound significance for the litigation. For months, Pfizer's primary legal argument — known as federal preemption — rested on the assertion that the FDA had previously reviewed and rejected a meningioma warning proposal, and therefore state-law failure-to-warn claims could not stand. The December 2025 label change directly dismantled that argument.

The timeline behind the warning is important context. In 2024, Pfizer submitted an initial meningioma warning proposal to the FDA — and the agency rejected it after a nine-month review. Pfizer subsequently used that rejection as the cornerstone of its preemption defense. However, in June 2025, Pfizer resubmitted a revised warning request. The FDA approved it in December 2025.^[2] Plaintiffs now argue that the FDA's ultimate approval proves Pfizer could have warned patients earlier and chose not to — a position that significantly strengthens thousands of failure-to-warn claims.

The warning has also accelerated case filings dramatically. Following the FDA announcement, the MDL case count jumped from approximately 1,752 in December 2025 to more than 3,490 by April 5, 2026 — nearly doubling in just four months.^[1]

MDL Status: The Fastest-Growing Mass Tort in America

The Depo-Provera litigation is formally consolidated as In re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, before Judge M. Casey Rodgers in the U.S. District Court for the Northern District of Florida, Pensacola Division. The MDL was centralized on February 7, 2025.

What has followed is a growth trajectory with few precedents in modern pharmaceutical litigation. The docket grew from approximately 130 cases when the MDL was first organized in April 2025, to 3,490 pending federal cases by April 5, 2026 — an increase of nearly 2,600% in twelve months.^[1]

When state court filings are included — with the largest concentrations in Delaware (287+ cases), New York (78+ cases), and California (39+ cases) — the total exceeds 4,000 actions across all U.S. courts.^[1] The current filing rate is estimated at approximately 650 new lawsuits per month.

Perhaps even more striking: attorneys across the country report an estimated 10,000 additional cases being held in reserve — unfiled claims awaiting the outcome of two critical rulings: the Daubert general causation hearing and a preemption decision. Judge Rodgers has specifically warned plaintiff leadership about this warehousing and ordered disclosure of unfiled case inventories. If the court's rulings favor plaintiffs, those 10,000 cases could flood the docket virtually overnight, creating enormous settlement pressure on Pfizer.

Key Upcoming Court Dates

• May 29, 2026: Daubert challenge briefs due — both sides submit expert admissibility arguments
• June 24–26, 2026: General causation Daubert hearing before Judge Rodgers — the court determines whether plaintiffs' scientific experts may testify at trial
• Preemption ruling: Pending — a pro-plaintiff ruling here validates the entire litigation; a pro-Pfizer ruling could be existential for many cases
• December 7–14, 2026: First bellwether trial — Blonski v. Pfizer Inc.
• January 2027: Four additional bellwether trials expected to begin

MDL leadership was formally reappointed in March 2026 under Pretrial Order No. 31. Lead counsel Christopher Seeger of Seeger Weiss LLP, co-lead counsel Bryan Aylstock of Aylstock Witkin Kreis & Overholtz, and co-lead counsel Ellen Relkin of Weitz & Luxenberg will continue steering the litigation through March 2027.^[5]

The Science: Four Studies That Established the Link

The Depo-Provera litigation is built on a foundation of peer-reviewed scientific evidence that has only strengthened since the landmark 2024 BMJ study. Four major studies now form the evidentiary backbone of plaintiffs' causation case — and each reached the same fundamental conclusion: long-term Depo-Provera use is associated with a materially elevated risk of developing an intracranial meningioma.

1. BMJ National Case-Control Study (March 2024)

The study that ignited the litigation, published in the British Medical Journal by Roland et al. from France's EPI-PHARE Scientific Interest Group, analyzed 18,061 women who underwent surgery for intracranial meningiomas between 2009 and 2018, compared against 90,305 matched controls.^[4]

2. University of British Columbia Cohort Study (May 2025)

A large population-based cohort study from UBC compared 72,181 Depo-Provera users against 247,180 users of other hormonal contraceptives. The study found an adjusted incident rate ratio of 3.55 for meningioma among women who used Depo-Provera for more than one year — a finding specifically replicated in a distinct North American population.^[6]

3. Cleveland Clinic Population Analysis (September 2025)

A Cleveland Clinic-associated analysis of more than 10 million women found that long-term Depo-Provera users were 2.5 times more likely to develop brain tumors than non-users. The analysis affirmed the duration-dependent risk pattern seen across other studies and was widely cited by attorneys and media outlets as corroborating evidence.^[7]

4. TriNetX U.S. Cohort Study (November 2025)

Leveraging the TriNetX national database covering 68 U.S. healthcare organizations with data spanning December 2004 through December 2024, this study found a relative risk of 2.43 (95% CI: 1.77–3.33) for meningioma diagnosis among Depo-Provera users compared to controls. Notably, the risk was concentrated in patients with more than four years of Depo-Provera exposure or those who began using the drug after age 31.^[8]

No other contraceptives analyzed in the TriNetX study showed elevated meningioma risk, strengthening the argument that the risk is specifically attributable to medroxyprogesterone acetate and not to hormonal contraceptives generally.

Taken together, these four independent studies — conducted across different countries, populations, and methodologies — consistently point to the same conclusion. This scientific convergence has been central to the FDA's decision to approve the meningioma warning and will form the basis of plaintiffs' expert testimony at the June 2026 Daubert hearing.

Pfizer's Preemption Defense — And Why It Collapsed

To understand the legal stakes in the Depo-Provera litigation, it is essential to understand Pfizer's primary defense: federal preemption. Under the preemption doctrine, when a federal agency (here, the FDA) has already reviewed and rejected a warning, a manufacturer cannot be required under state law to add that same warning independently. If successful, preemption would effectively shield Pfizer from liability in all state failure-to-warn claims.

Pfizer's preemption argument was initially built on a specific factual premise: that in 2024, the company submitted a proposed meningioma warning to the FDA, which the agency then rejected after a nine-month review. Pfizer argued that this rejection meant it lacked the regulatory authority to add the warning unilaterally, making state-law failure-to-warn claims legally impossible.

That argument took a serious blow in June 2025, when Pfizer resubmitted a revised warning request — and the FDA approved it in December 2025. The FDA's approval is now being used by plaintiffs to make two powerful counter-arguments:

• The warning was feasible all along: Because the FDA ultimately approved a meningioma warning, plaintiffs argue Pfizer could have submitted a stronger, better-evidenced proposal earlier and received approval sooner. The company's delay in adequately warning patients was a choice, not a regulatory constraint.
• The clean preemption narrative is gone: The FDA's own label change proves there is now regulatory acknowledgment of the meningioma risk — making it far harder for Pfizer to argue that state courts should defer to federal inaction.

Following the December 2025 FDA label change, Judge Rodgers ordered supplemental preemption briefing from both sides, which concluded February 27, 2026. A ruling on preemption is currently pending. Legal analysts following the case note that under Wyeth v. Levine (2009) — the Supreme Court's landmark pharmaceutical preemption precedent — drug makers bear a heavy burden to show that FDA approval was "clear evidence" that the agency would not have approved the warning. Given the FDA's December 2025 approval, that burden appears increasingly difficult for Pfizer to meet.

Per Pretrial Order No. 30, issued January 27, 2026, the court ruled that both the preemption and Daubert decisions will apply to all cases in the MDL simultaneously — making these two rulings existential moments for the entire litigation. A pro-plaintiff outcome on both could trigger rapid settlement negotiations with Pfizer, given the scale of exposure the company faces.

Settlement Projections: What Depo-Provera Cases May Be Worth

As of April 2026, no Depo-Provera meningioma cases have been settled, and Pfizer has not publicly offered settlement terms or acknowledged liability. All figures currently circulating are attorney projections based on injury severity, comparable pharmaceutical settlements, and general mass tort valuation frameworks. Actual settlement amounts — if and when they occur — may differ materially.

With those important caveats stated, plaintiff attorneys generally project individual case values based on a tiered severity system:

Attorneys representing plaintiffs with significant complications generally cite an average range of $275,000 to $500,000 for cases requiring surgery. For context, comparable pharmaceutical litigation provides useful benchmarks: the Yaz/Yasmin blood clot litigation, which involved roughly 10,300 claims, resolved at approximately $2.04 billion total — or roughly $212,000 to $220,000 per claim. Attorneys argue that Depo-Provera's brain tumor injuries are generally more severe than blood clot injuries, which should support higher per-case values.

The ultimate settlement trajectory will depend heavily on the June 2026 Daubert ruling, the preemption decision, and the verdict in the December 2026 Blonski bellwether trial. A plaintiff verdict in that first trial — even if appealed — would almost certainly accelerate settlement discussions significantly. Pfizer, with a market capitalization exceeding $150 billion, has the financial capacity for a large settlement program if the litigation proceeds to that stage.

The December 2026 Bellwether Trial: Blonski v. Pfizer

In mass tort litigation, bellwether trials serve as test cases — representative samples from the broader plaintiff pool selected to give both sides (and the court) an early read on how juries respond to the evidence. They rarely resolve the entire litigation on their own, but they carry enormous practical significance: a strong plaintiff verdict signals to the defendant that it faces serious exposure at scale and typically accelerates settlement discussions. A defense verdict shifts leverage in the opposite direction.

The first Depo-Provera bellwether — Blonski v. Pfizer Inc. — is scheduled for December 7–14, 2026 before Judge Rodgers in Pensacola. The plaintiff is a Florida woman who was a long-term Depo-Provera user and subsequently developed a meningioma, with reported symptoms including vertigo, dizziness, hearing loss, and neurological impairment requiring brain surgery.^[3]

The court has selected five pilot cases in total for the initial bellwether trial pool. Other named plaintiffs include:

• Schmidt v. Pfizer Inc. — plaintiff received approximately 64 Depo-Provera injections and was diagnosed with an intracranial meningioma requiring surgery
• Toney v. Pfizer Inc. — first injection in 1997; MRI revealed a meningioma that was subsequently removed surgically
• Wilson v. Pfizer Inc. — used Depo-Provera from 1998 through 2019

Four additional bellwether trials are expected to begin in January 2027. The December trial will be closely watched by every stakeholder in the litigation: plaintiffs' attorneys, Pfizer's legal team, insurance markets, and the thousands of women currently evaluating whether to file claims. A single jury's verdict in Pensacola will have ripple effects across the entire national litigation.

Who Qualifies to File a Depo-Provera Lawsuit

Plaintiff attorneys across the country are currently screening potential clients using a consistent set of eligibility criteria. While each case is evaluated individually, the following parameters describe who is most likely to have a viable Depo-Provera meningioma claim as of April 2026.

Core Eligibility Requirements

• Drug used: You must have received brand-name Depo-Provera CI (150 mg/mL injectable), Depo-SubQ Provera 104, or an authorized generic equivalent containing medroxyprogesterone acetate. Users of other hormonal contraceptives (pills, patches, IUDs, implants) using different active ingredients generally do not qualify.
• Minimum duration of use: Most attorneys require at least 12 months of use (approximately 4 or more injections, since each injection covers about 3 months). Cases with 4+ years of use are considered strongest based on the TriNetX study findings showing concentrated risk in long-term users.
• Confirmed meningioma diagnosis: You must have a confirmed intracranial meningioma diagnosis verified by MRI, CT imaging, and/or pathology report. Both benign (WHO Grade I) and higher-grade tumors (Grade II, Grade III) qualify. Grade II and III cases generally command higher damages due to severity. Spinal meningiomas may also qualify in some cases.
• Statute of limitations compliance: Your claim must be filed within your state's applicable statute of limitations, potentially extended by the discovery rule (see below).

Factors That Increase Case Value

• WHO Grade II or Grade III tumor classification
• Brain surgery required (craniotomy or stereotactic radiosurgery)
• Significant neurological deficits: vision loss, hearing loss, cognitive impairment, seizures, balance disorders
• Duration of Depo-Provera use exceeding four years
• First use of Depo-Provera after age 31 (the TriNetX study found elevated risk in this population)
• Death attributable to meningioma or surgical complications (wrongful death claims)

Documentation You Should Gather

• Prescription records, pharmacy records, or clinical injection logs confirming Depo-Provera use and duration
• MRI, CT scan, and/or pathology reports confirming meningioma diagnosis
• Surgical operative reports, if applicable
• Neurology or oncology records documenting treatment and ongoing care

If you cannot locate all of these records, an attorney can often assist with medical record retrieval. Partial documentation is not an automatic disqualifier — but complete documentation strengthens your case significantly.

Statute of Limitations — Act Before the Clock Runs Out

One of the most urgent practical concerns for potential Depo-Provera plaintiffs is the statute of limitations — the deadline by which a lawsuit must be filed. Every state sets its own limitations period for personal injury and product liability claims, ranging from as short as one year to as long as six years.

In most states, the limitations clock begins when you knew, or through reasonable diligence should have known, that your meningioma might be connected to Depo-Provera use — not necessarily when your last injection occurred or when the tumor was first diagnosed. This is known as the discovery rule.^[9]

Because the landmark BMJ study linking Depo-Provera to meningioma was only published in March 2024 — and because widespread public awareness of the connection only emerged in mid-to-late 2024 — many women may have strong arguments that their discovery rule clock did not begin until 2024 or 2025, regardless of when their last injection or diagnosis occurred. However, this legal argument must be made formally and proactively; it is not automatic.

Additional legal protections may be available in states that recognize equitable tolling for fraudulent concealment — meaning that if Pfizer is found to have withheld or concealed evidence of the meningioma risk, the limitations clock may not have begun running until the concealment was discovered. Attorneys will evaluate these state-specific defenses on a case-by-case basis.

The most important takeaway: if you believe you may have a claim, consult an attorney as soon as possible. Waiting costs you nothing except time — and in legal matters, time can cost you everything.

Frequently Asked Questions